United Therapeutics is a biotechnology company focused on the development and commercialization of medical treatment of cardiovascular and infectious diseases and cancer.

The group reported strong results for the first quarter of 2013 with total revenues of USD 245 million, up from USD 204 million which represents a 20% change. Gross margin from sales was USD 214 million compared to USD 179 million from the same quarter last year. The Thomson Reuters consensus revised regularly upward EPS estimates of the company for the current year.

From a technical viewpoint, after a strong bullish acceleration, prices could comeback on the USD 64 area (50% retracement of the last movement) to take advantage of the 20 and 50-day moving averages. The bullish trend line should help the stock to renew its upward trend in direction of the USD 72 level.

According to both technical and fundamental elements, it seems opportune to take a long position in the USD 64 area to benefit from a remobilisation of buyers. The target price will be the USD 72 level. A stop loss will be placed under the short term support to avoid a downtrend.